VM 523 Hemostasis II - Dr. Thomas

⭐ 1. Q: What is the big-picture purpose of the Hemostasis II Lecture?

The Hemostasis II lecture is how the body limits excessive clot formation and later removes fibrin from a clot.

🔎 What this means:

There are two major “brakes”:

• Endogenous anticoagulants slow or limit coagulation.

• Fibrinolysis breaks down fibrin after it has formed.

Think:

Hemostasis I = build the clot
Hemostasis II = control the clot + break it down when appropriate

Hemostasis I and II are not physiological processess, it is just how she decided to name the lecture and break it down into two parts

2. Q: What is a thrombus?

A thrombus is a clot that forms inside the cardiovascular system.

🔎 What this means:

A thrombus contains components such as platelets and fibrin.

If a thrombus forms excessively or in the wrong place, it can obstruct blood flow.

⭐ 3. Q: What is an endogenous anticoagulant?

An endogenous anticoagulant is a substance naturally produced by the body that limits coagulation.

🔎 What this means:

Endogenous = produced within the body.

These molecules act like brakes on the coagulation system so clotting does not spread uncontrollably.

⭐ 4. Q: What is antithrombin?

Antithrombin is an endogenous anticoagulant that inhibits many of the enzymes that activate coagulation

🔎 What this means:

Antithrombin is abbreviated:

AT or ATIII

Think:

Coagulation enzymes push clotting forward.
Antithrombin puts the brakes on those enzymes.

⭐ 5. Q: Where is antithrombin produced?

Antithrombin is produced by hepatocytes in the liver.

6. Q: What are heparan sulfate and heparin?

Heparan sulfate and heparin are closely related sulfated carbohydrate molecules that can help antithrombin inhibit coagulation enzymes.

🔎 What this means:

They are not proteins.

They are long carbohydrate chains called glycosaminoglycans.

Heparan sulfate

• naturally found on endothelial cell surfaces

• helps antithrombin physiologically

Heparin

• a closely related molecule

• commonly used therapeutically as an anticoagulant

7. Q: What is the main difference between heparan sulfate and heparin for this course?

Heparan sulfate is naturally present on endothelial cell surfaces, whereas heparin is presented as a therapeutic anticoagulant compound that can produce a similar antithrombin-enhancing effect.

🔎 What this means:

For your exam, the simplest distinction is:

Heparan sulfate → endothelial surface

Heparin → therapeutic drug

Both can help ATIII function.

⭐ 8. Q: How do heparan sulfate and heparin help antithrombin work?

Heparan sulfate or heparin binds to antithrombin and causes a conformational change that allows antithrombin to bind to coagulation enzymes more effectively and thus inhibit them.

🔎 What this means:

Heparan sulfate/heparin binds ATIII

→ ATIII changes shape

→ ATIII attaches to coagulation enzyme

→ enzyme becomes inactive

💡 Analogy:

ATIII = brake

Heparan sulfate/heparin = helps press the brake

⭐ 9. Q: How are endothelial cells connected to antithrombin?

Endothelial cells provide surface heparan sulfate that helps antithrombin bind and inhibit coagulation enzymes.

🧠 LECTURE QUIZ 10. Q: Which endogenous anticoagulant inhibits most coagulation enzymes?

Antithrombin inhibits most coagulation enzymes.

🧠 LECTURE QUIZ 11. Q: Which is directly inhibited by antithrombin III: factor Va, factor Xa, platelets, or tissue factor?

Factor Xa is directly inhibited by antithrombin III.

🔎 What this means:

ATIII primarily inhibits activated coagulation enzymes.

🧠 LECTURE QUIZ 12. Q: Which is NOT an endogenous anticoagulant: Protein C, antithrombin, tPA, or TFPI?

Tissue plasminogen activator, or tPA, is not classified as an endogenous anticoagulant

🔎 What this means:

tPA belongs to the fibrinolytic system.

The other choices are endogenous anticoagulants.

⭐ 13. Q: Why can decreased antithrombin increase the risk of thrombosis?

Decreased antithrombin reduces inhibition of coagulation enzymes, shifting hemostatic balance toward excessive clot formation.

⭐ 14. Q: What is fibrinolysis?

Fibrinolysis is tertiary hemostasis, the controlled process that breaks down fibrin and helps limit or remove thrombi.

It also helps restore blood flow and revascularization.

⭐ 15. Q: How do secondary and tertiary hemostasis differ?

Secondary hemostasis produces fibrin to stabilize a clot, whereas tertiary hemostasis breaks fibrin down.

🔎 What this means:

Think:

Secondary = build fibrin 🧱

Tertiary = remove fibrin ✂

Both are necessary for normal hemostatic balance.

⭐ 16. Q: What is plasminogen?

Plasminogen is an inactive enzyme precursor produced by the liver that can be activated to form plasmin which then goes on to break down fibrin

tPA activates plasminogen → plasmin is formed → plasmin breaks down fibrin

🔎 What this means:

Plasminogen circulates in plasma.

Plasminogen = inactive form

17. Q: What is a zymogen?

A zymogen is an inactive enzyme precursor that must be activated before it can function as an enzyme.

“Zymogen” is not the name of a particular molecule, it is a category. A zymogen is basically the inactive form of an enzyme.

The purpose of zymogens is to keep powerful enzymes in an inactive state, until they are actually needed.

For example:

Plasminogen is the zymogen of Plasmin
Prothrombin is the zymogen of Thrombin

⭐ 18. Q: What is plasmin?

Plasmin is the active fibrinolytic enzyme that breaks down fibrin.

🧠 LECTURE QUIZ 19. Q: What is the major fibrinolytic enzyme?

Plasmin is the major fibrinolytic enzyme.

⭐ 20. Q: What is tissue plasminogen activator, or tPA?

Tissue plasminogen activator is a molecule released by activated endothelial cells that promotes the conversion of plasminogen into plasmin.

🔎 What this means:

The name basically tells you the job:

plasminogen activator → activates plasminogen

So:

tPA → plasminogen → plasmin

🧠 LECTURE QUIZ 21. Q: What is the major activator involved in generating plasmin?

Tissue plasminogen activator, or tPA, is the major activator involved in generating plasmin.

🔎 What this means:

tPA starts the important activation step of fibrinolysis.

⭐ 22. Q: What is the core pathway of fibrinolysis?

tPA (tissue plasminogen activator) promotes the activation of plasminogen into plasmin, and plasmin then breaks down fibrin into degradation products.

🔎 What this means:

Know this pathway cold:

tPA → plasminogen → plasmin → fibrin breakdown

⭐ 23. Q: Why does plasmin not break down fibrin everywhere in the circulation?

Fibrinolytic activity is localized mainly to thrombi, and free plasmin is rapidly inhibited by antiplasmin.

🔎 What this means:

Plasmin is useful at the clot.

Free plasmin elsewhere is quickly shut down.

That helps keep fibrinolysis controlled.

24. Q: What is antiplasmin?

Antiplasmin is an inhibitor that rapidly inactivates free plasmin.

⭐ 25. Q: What is plasminogen activator inhibitor, or PAI?

Plasminogen activator inhibitor is an endothelial-cell product that inhibits tPA (tissue plasminogen activator) and therefore reduces plasmin formation.

🔎 What this means:

PAI acts upstream of plasmin:

PAI blocks tPA → less plasminogen activation → less plasmin → less fibrinolysis

26. Q: How do antiplasmin and PAI differ?

Antiplasmin inhibits plasmin directly, whereas PAI inhibits tPA and therefore prevents plasmin from being generated.

⭐ 27. Q: What are fibrin degradation products, or FDPs?

FDPs are fragments produced when plasmin breaks down fibrinogen or fibrin.

🔎 What this means:

Think of FDPs as debris left after plasmin cuts proteins apart.

Important:

FDPs can come from:

• fibrinogen

• fibrin

⭐ 28. Q: What is a D-dimer?

A D-dimer is a fibrin degradation product (FDP) produced specifically when cross-linked fibrin is broken down.

The confusing part is that “cross-linked fibrin” sounds like a special type of fibrin, when really it is better thought of as a later, strengthened state of fibrin.

🔎 What this means:

A D-dimer is a special type of FDP.

To produce one:

fibrin must form → fibrin must be cross-linked → fibrinolysis must break it down

⭐ 29. Q: What is the major difference between FDPs and D-dimers?

FDPs can come from breakdown of fibrinogen or fibrin, whereas D-dimers come specifically from breakdown of cross-linked fibrin.

🧠 LECTURE QUIZ 30. Q: What products can plasmin generate?

Plasmin can generate FDPs, including D-dimers when cross-linked fibrin is degraded.

🧠 LECTURE QUIZ 31. Q: What does an increased D-dimer concentration indicate?

An increased D-dimer indicates that both coagulation and fibrinolysis have occurred.

🔎 What this means:

For D-dimer to exist:

1. fibrin had to form,

2. fibrin had to become cross-linked,

3. that cross-linked fibrin then had to be broken down.

So:

D-dimer → clot formed AND clot breakdown occurred.

⭐ 32. Q: What are the two major tests used to evaluate fibrinolysis?

The two major tests are FDP concentration and D-dimer concentration.

🔎 What this means:

Their major difference is what they detect:

FDPs → fibrinogen or fibrin breakdown

D-dimers → cross-linked fibrin breakdown

⭐ 33. Q: How can excessive or insufficient fibrinolysis affect the patient?

Excessive fibrinolysis can promote bleeding from insufficient clot formation, whereas insufficient fibrinolysis can promote thrombosis or “too much clot.”

🔎 What this means:

Too much clot breakdown:

↑ fibrinolysis → bleeding tendency

Too little clot breakdown:

↓ fibrinolysis → thrombi persist → thrombosis

34. Q: How can FDPs themselves interfere with hemostasis?

Hemostasis is the body’s overall system for preventing excessive bleeding while also preventing excessive clotting.

FDPs can interfere with platelet aggregation (platelets sticking together) and fibrin formation because they compete with fibrinogen for platelet fibrinogen receptors.

In other words, they interfere with the formation of platelet bridges and thus dec. platelet aggregation

🔎 What this means:

They have two antithrombotic effects:

Antiplatelet:
FDPs compete with fibrinogen for platelet fibrinogen receptors.

Anticoagulant:
FDPs bind thrombin and interfere with fibrin formation.

🧠 LECTURE QUIZ 35. Q: How do FDPs directly impair coagulation?

FDPs bind to thrombin and interfere with the formation of fibrin from fibrinogen. They also compete with fibrinogen for platelet fibrinogen receptors, causing a decrease in platelet bridges/aggregation

🧠 LECTURE QUIZ 36. Q: What can cause increased FDP and D-dimer concentrations?

Increased tPA (tissue plasminogen activator) activity can increase plasmin generation and promote breakdown of fibrinogen and cross-linked fibrin.

🔎 What this means:

More tPA can mean:

↑ plasmin → ↑ protein breakdown → ↑ FDPs and D-dimers

⭐ 37. Q: What is an endothelial cell?

An endothelial cell is a cell that lines the inside of a blood vessel and actively helps regulate hemostasis.

⭐ 38. Q: What antithrombotic activities predominate in healthy resting endothelial cells?

Antithrombotic means opposing the formation of clots

Resting endothelial cells inhibit platelets and coagulation, and promotes fibrinolysis.

🔎 What this means:

Three categories:

Antiplatelet

• NO, Nitric Oxide

• PGI₂, Prostacyclin

• ADP inhibitor

• All of these inhibit platelet formation

Anticoagulant

• heparan sulfate, helps ATIII

• thrombomodulin, helps anticoagulant pathways

Profibrinolytic

• tPA promotes plasmin formation

Think:

Healthy endothelium says: “Do NOT clot here.”

🧠 LECTURE QUIZ 39. Q: Which is an antithrombotic property of endothelial cells: VWF secretion, heparan sulfate, tissue factor, or PAI secretion?

Surface expression of heparan sulfate is an antithrombotic property of endothelial cells.

⭐ 40. Q: What prothrombotic activities predominate when endothelial cells are injured or activated?

⭐ 40. Q: What prothrombotic activities predominate when endothelial cells are injured or activated?

Activated endothelial cells promote platelet activity and coagulation while inhibiting fibrinolysis.

🔎 What this means:

They:

Promote platelets

• increase VWF

• release platelet activators

• increase adhesion molecules

• decrease platelet inhibitors

Promote coagulation

• express tissue factor

• decrease anticoagulant mechanisms

Reduce fibrinolysis

• produce PAI

Think:

Activated endothelium says: “We are injured. Clot here.”

⭐ 41. Q: How does activated endothelium inhibit fibrinolysis?

Activated endothelial cells secrete PAI, which inhibits tPA and therefore decreases plasmin formation and fibrin breakdown.

🔎 What this means:

Follow the chain:

↑ PAI → ↓ tPA → ↓ plasmin → ↓ fibrinolysis

This helps the new thrombus remain intact while the injury is being addressed.

🧠 LECTURE QUIZ 42. Q: Which is a prothrombotic property of endothelial cells: VWF secretion, thrombomodulin, tPA, or platelet inhibitors?

Von Willebrand factor secretion is a prothrombotic property of endothelial cells.

🔎 What this means:

VWF promotes platelet adhesion to the injured vessel wall.

⭐ 43. Q: What changes can shift hemostasis toward thrombosis?

Increased platelet activity, increased coagulation, decreased fibrinolysis, decreased anticoagulant activity, or endothelial dysfunction can promote thrombosis.

🔎 What this means:

There is no single “thrombosis pathway.”

Thrombosis occurs when the overall balance becomes too pro-clotting.

⭐ 44. Q: What changes can shift hemostasis toward bleeding?

Reduced platelet activity, reduced coagulation, excessive fibrinolysis, excessive anticoagulant activity, or some endothelial abnormalities can promote bleeding.

🔎 What this means:

The system works like a balance:

Too much clot formation → thrombosis

Too little clot formation or too much clot breakdown → bleeding